Telomerase as a diagnostic and predictive marker in colorectal carcinoma

被引:0
|
作者
Maláska, J
Kunická, Z
Borsky, M
Sklenicková, M
Novotná, M
Fajkusová, L
Zaloudík, J
Fajkus, J [1 ]
机构
[1] Acad Sci Czech Republ, Inst Biophys, CS-61265 Brno, Czech Republic
[2] Masaryk Mem Canc Inst, Brno, Czech Republic
[3] Masaryk Univ, Dept Funct Genom & Proteom, Brno, Czech Republic
[4] Univ Hosp Brno, Dept Internal Med & Hematooncol, Ctr Mol Biol & Gene Therapy, Brno, Czech Republic
关键词
colorectal carcinoma; telomerase; diagnostic and predictive marker;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a search for molecular markers providing both informative diagnostics of malignant disease, and rational stratification of a therapeutic strategy to achieve optimal response in a given patient, we examined the possibility of using telomerase for this purpose in colorectal cancer. Telomerase, a ribonucleoprotein enzyme complex catalysing synthesis of chromosome ends (telomeres), has been known as an almost universal tumor marker but its predictive value has been found in only a limited number of malignant tumor types. Telomerase activity and expression of its catalytic subunit hTERT was determined in 82 surgical specimens from 41 patients (a sample of tumor tissue and of adjacent Morphologically normal tissue was obtained from each patient). Telomerase activity was present in tumor samples from 34 (83%) patients, reaching an average value of 47.6 telomerase units (T.U.), while adjacent tissue specimens were either negative (in 25 (61%) patients), or slightly positive (in 16 (39%) patients) showing 1.5 T.U. on average. In tumor samples from patients without lymphatic node metastases (pN0), an average of 37.1 T.U was found. In contrast, in tumor samples from patients with lymphatic node involvement (pN1 or pN2) the average activity was significantly higher (60.2 T.U., p<0.05). In patients with distant metastases a tendency towards higher telomerase activity, although lacking statistical significance, could be observed. Among patients that obtained chemotherapy with 5-fluoruracil, those with low telomerase activity showed a ten-dency to chemosensitivity. Expression of hTERT was detected not only in samples showing telomerase activity, but also in a considerable portion of telomerase-negative samples either from the tumor or the adjacent normal tissue. We demonstrate that some of these apparent discrepancies may be attributed to differential splicing of hTERT mRNA. We conclude that TRAP assay for telomerase activity is more informative than the common testing for hTERT expression. Telomerase activity is useful both as a diagnostic as well as a predictive factor in colorectal cancer.
引用
收藏
页码:90 / 96
页数:7
相关论文
共 50 条
  • [31] Vimentin Methylation as a Marker for Advanced Colorectal Carcinoma
    Shirahata, Atsushi
    Sakata, Makiko
    Sakuraba, Kazuma
    Goto, Tetsuhiro
    Mizukami, Hiroki
    Saito, Mitsuo
    Ishibashi, Kazuyoshi
    Kigawa, Gaku
    Nemoto, Hiroshi
    Sanada, Yutaka
    Hibi, Kenji
    ANTICANCER RESEARCH, 2009, 29 (01) : 279 - 281
  • [32] Baseline lymphopenia as a prognostic marker for colorectal carcinoma
    Erdem, Dilek
    Yucel, Idris
    Yilmaz, Bahiddin
    Demirag, Guzin
    Kemal, Yasemin
    Teker, Fatih
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Evaluation of Human Telomerase Activity as a Novel Tumor Marker for Hepatocellular Carcinoma
    Hady, Afaf Abdel
    El Shanawany, Faten
    Hassan, Mona M.
    Anas, Amgad
    Mostafa, Ibrahim
    Hadi, Ahmed Abdel
    LIFE SCIENCE JOURNAL-ACTA ZHENGZHOU UNIVERSITY OVERSEAS EDITION, 2010, 7 (04): : 153 - 161
  • [34] Keratin 20 - A diagnostic and prognostic marker in colorectal cancer?
    Harbaum, Lars
    Pollheimer, Marion J.
    Kornprat, Peter
    Lindtner, Richard A.
    Schlemmer, Andrea
    Rehak, Peter
    Langner, Cord
    HISTOLOGY AND HISTOPATHOLOGY, 2012, 27 (03) : 347 - 356
  • [35] Clusterin in stool: A new diagnostic marker of colorectal cancer
    Pucci, S.
    Sesti, F.
    Mazzarelli, P.
    Bonanno, E.
    Spagnoli, L. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Telomerase activity in stage II colorectal carcinoma - Telomerase-negative tumors are correlated with poor prognosis
    Kawanishi-Tabata, R
    Lopez, F
    Fratantonio, S
    Kim, N
    Goldblum, J
    Tubbs, R
    Elson, P
    Lavery, I
    Bukowski, RM
    Ganapathi, R
    Ganapathi, MK
    CANCER, 2002, 95 (09) : 1834 - 1839
  • [37] Telomerase as tumor marker
    Hiyama, E
    Hiyama, K
    CANCER LETTERS, 2003, 194 (02) : 221 - 233
  • [38] Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma
    Li, Jun
    Cheng, Zhang-Jun
    Liu, Yang
    Yan, Zhen-Lin
    Wang, Kui
    Wu, Dong
    Wan, Xu-Ying
    Xia, Yong
    Lau, Wan Yee
    Wu, Meng-Chao
    Shen, Feng
    ONCOTARGET, 2015, 6 (11) : 9551 - 9563
  • [39] Telomerase as a marker for cancer
    Abdulla, S
    MOLECULAR MEDICINE TODAY, 1997, 3 (05): : 187 - 187
  • [40] PinX1 suppresses tumorigenesis by negatively regulating telomerase/telomeres in colorectal carcinoma cells and is a promising molecular marker for patient prognosis
    Qian, Dong
    Cheng, Jingjing
    Ding, Xiaofeng
    Chen, Xiuli
    Chen, Xi
    Guan, Yong
    Zhang, Bin
    Wang, Jiefu
    Er, Puchun
    Qiu, Minghan
    Zeng, Xianliang
    Guo, Yihang
    Wang, Huanhuan
    Zhao, Lujun
    Xie, Dan
    Yuan, Zhiyong
    Wang, Ping
    Pang, Qingsong
    ONCOTARGETS AND THERAPY, 2016, 9 : 4821 - 4831